Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide

International Journal of Pharmaceutics

Volumn 194, Issue 2, 2000, Pages 181-191

  Ravivarapu, Harish B ^a   Moyer, Katie L ^a   Dunn, Richard L ^a  

^a QLT Inc   (United States)

Author keywords

Dogs; Formulation parameters; In situ implant; Leurpolide acetate; Rats; Testosterone suppression

Indexed keywords

LEUPRORELIN; POLYGLACTIN;

ARTICLE; DRUG DETERMINATION; DRUG FORMULATION; DRUG IMPLANT; MOLECULAR WEIGHT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SUSPENSION; SUSTAINED RELEASE PREPARATION; VISCOSITY;

ANIMALS; DELAYED-ACTION PREPARATIONS; DOGS; DRUG IMPLANTS; HUMANS; LACTIC ACID; LEUPROLIDE; MALE; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SUSPENSIONS; TESTOSTERONE;

EID: 0033963035     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00371-3     Document Type: Article

References (14)

1. Caulcutt R. Statistics in Research and Development. first ed:1983;Chapman and Hall, New York.
2. Dunn, R.L., Tipton, A.J., 1997. Polymeric compositions useful as controlled release implants. US Patent 5,702,716.
3. Dunn, R.L., English, J.P., Cowsar, D.R., Vanderbilt, D.P., 1990. Biodegradable in situ forming implants and methods of producing the same. US Patent 4,938,763.
4. Garnick M.B. Leuprolide versus diethylstilbestrol for metastatic cancer. New Engl. J. Med. 311:1984;1281-1286.
5. Lemay A., Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a leutinizing hormone-releasing hormone (LHRH) agonist. Fertil. Steril. 38:1982;376-379.
6. Okada H., Toguchi H. Biodegradable microspheres in drug delivery. Clin. Rev. Ther. Drug Sys. 12(1):1995;1-99.
7. Okada H., Sakura Y., Kawaji T., Yashiki T., Mima H. Regression of rat mammary tumors by a potent leutinizing hormone-releasing hormone (leuprolide) administered vaginally. Cancer Res. 43:1983;1869-1874.
8. Okada H., Heya T., Ogawa Y., Toguchi H., Shimamoto T. Sustained pharmacological activities in rats following single and repeated administration of once-a month injectable microspheres of leuprolide acetate. Pharm. Res. 8(5):1991;584-587.
9. Okada H., Inoue Y., Heya T., Ueno H., Ogawa Y., Toguchi H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8(6):1991;787-791.
10. Plosker G.L., Brodgen R.N. Leuprorelin. A review of its pharmacology and therapeutic use in prostate cancer, endometriosis and other sex hormone-related disorders. Drugs. 48(6):1994;930-967.
11. 6 analogue of leutinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA. 78:1981;6509-6512.
12. Ravivarapu, H.B., Moyer, K.L., Dunn, R.L., 1999. Sustained suppression of pituitary-gonodal axis with an injectable, in situ forming implant of leuprolide acetate. J. Pharm. Sci. (submitted).
13. Sharifi R., Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urol. 143:1990;68-71.
14. Sutherland J.W., Menon G.N. HPLC of leuprolide acetate in injectable solutions. J. Liq. Chromat. 10(10):1987;2281-2289.